Drug affordability
The EU evaluates affordability and availability of medicines
  • July 5, 2016
  • Valid Insight

Drug prices are rising across the European Union, and in economically-difficult times this is having an impact on drug affordability and accessibility. The European Union health ministers have met to discuss the impact of the situation, and make decisions that could change the way that drugs are priced across the region. These conclusions were published […]

Speeding drugs to market using adaptive pathways
  • June 28, 2016
  • Valid Insight

For parents of children with serious disorders where there is no approved treatment, or physicians who have tried everything for their patients with terminal diseases, the wait for approval of innovative drugs is a long one. The European Medicines Agency’s adaptive pathways pilot project aims to allow patients and their physicians to access life-changing or […]

Valid Insight
Standardising evidence generation: EUnetHTA’s HTA core model
  • June 22, 2016
  • Valid Insight

EUnetHTA is a network of health technology assessment (HTA) bodies across Europe. This cross-border group aims to standardise evidence generation, and support decision-making by working together, in order to add value to the HTA process at regional, national and European levels. This will be achieved through the best use of resources, and by sharing knowledge […]

Patient Data
New sources of patient data to support product value
  • June 8, 2016
  • Valid Insight

Real-world data is a vital part of market access today, and there are a variety of different sources of patient data to work with ranging from observational data collected from claims databases and patient records, through to some of the outputs from registries and monitoring platforms linked to accelerated approval processes. Data direct from patients […]

Accelerate market access
Regulatory initiatives to accelerate market access – UK, Japan and USA edition
  • May 25, 2016
  • Valid Insight

Accelerated pathways are emerging in individual countries that are designed to speed therapies through the approvals process and onto the market for patients who have unmet needs. Following on from our EU focus, in this post we look at the key schemes to date, that are in place in the UK, Japan and USA to […]

accelerate market access
EU regulatory initiatives can accelerate market access to new medicines
  • May 18, 2016
  • Valid Insight

The drug development process is a long one – depending on the specific therapeutic and disease, it can take up to 15 years for a product to be ready for market access. Once a drug is submitted to the European Medicines Agency (EMA) for marketing authorisation, the agency aims to issue an opinion within 210 […]

Valid Insight
The impact of austerity on global pharma pricing and access
  • May 10, 2016
  • Valid Insight

Austerity has been the buzzword for governments around the globe, as economies fight deficits and economic downturns. The combination of austerity, along with the aging population and the rising cost of therapeutics, means that healthcare is one of the areas particularly hit by the financial challenges. In order to ensure that the right patients can […]

Market access strategy
Understanding payers’ real-world needs
  • April 27, 2016
  • Valid Insight

All of the stakeholders involved in drug development and market access would like the right treatments to be available to the right patients, but in times of increasing austerity drug costs make this challenging. Payers need to see the value of a drug outside a clinical trial and in a real-world setting, in order to […]

Marker Access
Market access: are payers adversaries or partners to better patient outcomes?
  • April 19, 2016
  • Valid Insight

For many years, the route to market access has been focused around completing clinical trials and meeting the safety and efficacy data needs of the regulators. This data is then used to persuade payers that the therapeutic is safe and works, and is therefore worth paying the price demanded. However, as budget cuts bite, competition […]

Market Access Strategy
Preparing your best market access strategy
  • April 12, 2016
  • Valid Insight

When thinking about getting new pharmaceuticals to the market, many companies focus efforts on getting products through approval, and so tailor their market access strategy to meeting the regulators’ needs. However, for a successful market access, any company needs to have a strategy to meet the needs of the payers as well as the regulators. Planning […]